Progression of structural damage is not related to rituximab serum levels in rheumatoid arthritis patients

Maria Boumans; Onno Teng; Rogier Thurlings; Johannes Bijlsma; Danielle Gerlag; Tom Huizinga; Koen Vos; Steven Stapel; Gertjan Wolbink; Janneke Tekstra; Jaap van Laar; Paul P Tak

doi:10.1093/rheumatology/ket137

Progression of structural damage is not related to rituximab serum levels in rheumatoid arthritis patients

Maria Boumans, Onno Teng, Rogier Thurlings, Johannes Bijlsma, Danielle Gerlag, Tom Huizinga, Koen Vos, Steven Stapel, Gertjan Wolbink, Janneke Tekstra, Jaap van Laar, Paul P Tak

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

OBJECTIVE: The most cost-effective dosing regimen for rituximab treatment in RA is currently unknown. The objective of this study is to determine whether low rituximab serum levels are associated with progression of structural damage in RA patients.

METHODS: Sixty-two RA patients were treated with rituximab in three different centres. Structural damage was assessed on radiographs of hands and feet before and 1 year after therapy using the Sharp-van der Heijde scoring method (SHS). Patients were divided into progressors vs non-progressors based on different cut-off values. Rituximab serum levels were measured by sandwich ELISA after 4 and 12 weeks (Leiden University Medical Center and University Medical Centre, Utrecht cohorts) or 4 and 16 weeks (Academic Medical Center/University of Amsterdam cohort).

RESULTS: There was no difference in rituximab levels between progressors and non-progressors 4 weeks and 12 or 16 weeks after initiation of treatment in the different cohorts. There was also no correlation between rituximab levels at week 4 or week 12 or 16 and change in SHS score after 1 year.

CONCLUSION: Low rituximab serum levels are not associated with progression of structural damage in RA patients. The results do not support the use of dosages higher than 2 × 1000 mg rituximab to inhibit progression of joint destruction.

Original language	English
Pages (from-to)	1462-6
Number of pages	5
Journal	Rheumatology (Oxford, England)
Volume	52
Issue number	8
DOIs	https://doi.org/10.1093/rheumatology/ket137
Publication status	Published - Aug 2013

Keywords

Adult
Aged
Aged, 80 and over
Antibodies, Monoclonal, Murine-Derived
Antirheumatic Agents
Arthritis, Rheumatoid
Arthrography
Cohort Studies
Disease Progression
Dose-Response Relationship, Drug
Drug Administration Schedule
Female
Foot
Hand
Humans
Male
Middle Aged
Prognosis
Prospective Studies
Rituximab
Sensitivity and Specificity
Statistics, Nonparametric
Young Adult
Comparative Study
Journal Article

Access to Document

10.1093/rheumatology/ket137

Cite this

@article{8f3ba1699d0a4a47acf5cbc7db123024,

title = "Progression of structural damage is not related to rituximab serum levels in rheumatoid arthritis patients",

abstract = "OBJECTIVE: The most cost-effective dosing regimen for rituximab treatment in RA is currently unknown. The objective of this study is to determine whether low rituximab serum levels are associated with progression of structural damage in RA patients.METHODS: Sixty-two RA patients were treated with rituximab in three different centres. Structural damage was assessed on radiographs of hands and feet before and 1 year after therapy using the Sharp-van der Heijde scoring method (SHS). Patients were divided into progressors vs non-progressors based on different cut-off values. Rituximab serum levels were measured by sandwich ELISA after 4 and 12 weeks (Leiden University Medical Center and University Medical Centre, Utrecht cohorts) or 4 and 16 weeks (Academic Medical Center/University of Amsterdam cohort).RESULTS: There was no difference in rituximab levels between progressors and non-progressors 4 weeks and 12 or 16 weeks after initiation of treatment in the different cohorts. There was also no correlation between rituximab levels at week 4 or week 12 or 16 and change in SHS score after 1 year.CONCLUSION: Low rituximab serum levels are not associated with progression of structural damage in RA patients. The results do not support the use of dosages higher than 2 × 1000 mg rituximab to inhibit progression of joint destruction.",

keywords = "Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Murine-Derived, Antirheumatic Agents, Arthritis, Rheumatoid, Arthrography, Cohort Studies, Disease Progression, Dose-Response Relationship, Drug, Drug Administration Schedule, Female, Foot, Hand, Humans, Male, Middle Aged, Prognosis, Prospective Studies, Rituximab, Sensitivity and Specificity, Statistics, Nonparametric, Young Adult, Comparative Study, Journal Article",

author = "Maria Boumans and Onno Teng and Rogier Thurlings and Johannes Bijlsma and Danielle Gerlag and Tom Huizinga and Koen Vos and Steven Stapel and Gertjan Wolbink and Janneke Tekstra and {van Laar}, Jaap and Tak, {Paul P}",

year = "2013",

month = aug,

doi = "10.1093/rheumatology/ket137",

language = "English",

volume = "52",

pages = "1462--6",

journal = "Rheumatology (Oxford, England)",

issn = "1462-0324",

publisher = "Oxford University Press",

number = "8",

}

TY - JOUR

T1 - Progression of structural damage is not related to rituximab serum levels in rheumatoid arthritis patients

AU - Boumans, Maria

AU - Teng, Onno

AU - Thurlings, Rogier

AU - Bijlsma, Johannes

AU - Gerlag, Danielle

AU - Huizinga, Tom

AU - Vos, Koen

AU - Stapel, Steven

AU - Wolbink, Gertjan

AU - Tekstra, Janneke

AU - van Laar, Jaap

AU - Tak, Paul P

PY - 2013/8

Y1 - 2013/8

N2 - OBJECTIVE: The most cost-effective dosing regimen for rituximab treatment in RA is currently unknown. The objective of this study is to determine whether low rituximab serum levels are associated with progression of structural damage in RA patients.METHODS: Sixty-two RA patients were treated with rituximab in three different centres. Structural damage was assessed on radiographs of hands and feet before and 1 year after therapy using the Sharp-van der Heijde scoring method (SHS). Patients were divided into progressors vs non-progressors based on different cut-off values. Rituximab serum levels were measured by sandwich ELISA after 4 and 12 weeks (Leiden University Medical Center and University Medical Centre, Utrecht cohorts) or 4 and 16 weeks (Academic Medical Center/University of Amsterdam cohort).RESULTS: There was no difference in rituximab levels between progressors and non-progressors 4 weeks and 12 or 16 weeks after initiation of treatment in the different cohorts. There was also no correlation between rituximab levels at week 4 or week 12 or 16 and change in SHS score after 1 year.CONCLUSION: Low rituximab serum levels are not associated with progression of structural damage in RA patients. The results do not support the use of dosages higher than 2 × 1000 mg rituximab to inhibit progression of joint destruction.

AB - OBJECTIVE: The most cost-effective dosing regimen for rituximab treatment in RA is currently unknown. The objective of this study is to determine whether low rituximab serum levels are associated with progression of structural damage in RA patients.METHODS: Sixty-two RA patients were treated with rituximab in three different centres. Structural damage was assessed on radiographs of hands and feet before and 1 year after therapy using the Sharp-van der Heijde scoring method (SHS). Patients were divided into progressors vs non-progressors based on different cut-off values. Rituximab serum levels were measured by sandwich ELISA after 4 and 12 weeks (Leiden University Medical Center and University Medical Centre, Utrecht cohorts) or 4 and 16 weeks (Academic Medical Center/University of Amsterdam cohort).RESULTS: There was no difference in rituximab levels between progressors and non-progressors 4 weeks and 12 or 16 weeks after initiation of treatment in the different cohorts. There was also no correlation between rituximab levels at week 4 or week 12 or 16 and change in SHS score after 1 year.CONCLUSION: Low rituximab serum levels are not associated with progression of structural damage in RA patients. The results do not support the use of dosages higher than 2 × 1000 mg rituximab to inhibit progression of joint destruction.

KW - Adult

KW - Aged

KW - Aged, 80 and over

KW - Antibodies, Monoclonal, Murine-Derived

KW - Antirheumatic Agents

KW - Arthritis, Rheumatoid

KW - Arthrography

KW - Cohort Studies

KW - Disease Progression

KW - Dose-Response Relationship, Drug

KW - Drug Administration Schedule

KW - Female

KW - Foot

KW - Hand

KW - Humans

KW - Male

KW - Middle Aged

KW - Prognosis

KW - Prospective Studies

KW - Rituximab

KW - Sensitivity and Specificity

KW - Statistics, Nonparametric

KW - Young Adult

KW - Comparative Study

KW - Journal Article

U2 - 10.1093/rheumatology/ket137

DO - 10.1093/rheumatology/ket137

M3 - Article

C2 - 23620560

SN - 1462-0324

VL - 52

SP - 1462

EP - 1466

JO - Rheumatology (Oxford, England)

JF - Rheumatology (Oxford, England)

IS - 8

ER -

Progression of structural damage is not related to rituximab serum levels in rheumatoid arthritis patients

Abstract

Keywords

Access to Document

Fingerprint

Cite this